Ottina, Eleonora http://orcid.org/0000-0002-9630-496X
Panova, Veera http://orcid.org/0000-0001-8433-6430
Doglio, Laura
Kazachenka, Anastasiya
Cornish, Georgina
Kirkpatrick, Joanna
Attig, Jan http://orcid.org/0000-0002-2159-2880
Young, George R. http://orcid.org/0000-0002-1203-588X
Litchfield, Kevin http://orcid.org/0000-0002-3725-0914
Lesluyes, Tom http://orcid.org/0000-0003-2251-5884
Van Loo, Peter http://orcid.org/0000-0003-0292-1949
Swanton, Charles http://orcid.org/0000-0002-4299-3018
MacRae, James http://orcid.org/0000-0002-1464-8583
Tüting, Thomas http://orcid.org/0000-0001-7146-0934
Kassiotis, George http://orcid.org/0000-0002-8457-2633
Article History
Received: 11 January 2021
Revised: 14 May 2021
Accepted: 1 June 2021
First Online: 18 June 2021
Change Date: 29 July 2021
Change Type: Update
Change Details: The name of Peter Van Loo was given incorrect in HTML version of the article. Correct is: Given name: Peter Family name: Van Loo
Competing interests
: GK is a scientific co-founder of EnaraBio and a member of its scientific advisory board. GK and GRY are consulting for EnaraBio. CS acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc (collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board member and Chief Investigator for the MeRmaiD1 clinical trial, has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi, Bicycle Therapeutics, and the Sarah Cannon Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL, and has stock options and is co-founder of Achilles Therapeutics.